Extended Data Fig. 2From: Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKaplan-Meier plots of progression-free survival (A) and overall survival (B) by cohort.Source dataBack to article page
